scholarly journals The Cancer-Associated Virus Landscape in HIV Patients with Oral Hairy Leukoplakia, Kaposi's Sarcoma, and Non-Hodgkin Lymphoma

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Peter D. Burbelo ◽  
Joseph A. Kovacs ◽  
Jason Wagner ◽  
Ahmad Bayat ◽  
Craig S. Rhodes ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Hiv Positive ◽  
Infectious Agents ◽  
Hiv Patients ◽  
Non Hodgkin Lymphoma ◽  
Oral Hairy Leukoplakia ◽  
Hairy Leukoplakia ◽  
Antibody Levels

Although HIV-positive patients are at higher risk for developing a variety of infection-related cancers, the prevalence of infections with the seven known cancer-associated viruses has not been studied. Luciferase immunoprecipitation systems were used to evaluate antiviral antibodies in four 23-person groups: healthy blood donors and HIV-infected patients with oral hairy leukoplakia (OLP), Kaposi's sarcoma (KS), or non-Hodgkin lymphoma (NHL). Antibody profiling revealed that all HIV-positive individuals were strongly seropositive for anti-gp41 and antireverse transcriptase antibodies. However, anti-p24 HIV antibody levels were highly variable and some OLP and KS patients demonstrated weak or negative responses. Profiling two EBV antigens revealed no statistical difference in antibody levels among the three HIV-infected groups. A high frequency of KSHV infection was detected in HIV patients including 100% of KS, 78% of OLP, and 57% of NHL patients. Most HIV-infected subjects (84%) showed anti-HBV core antibodies, but only a few showed antibodies against HCV. MCV seropositivity was also common (94%) in the HIV-infected individuals and KS patients showed statistically higher antibody levels compared to the OLP and NHL patients. Overall, 68% of the HIV-infected patients showed seropositivity with at least four cancer-associated viruses. Antibody profiles against these and other infectious agents could be useful for enhancing the clinical management of HIV patients.

PERILOUS HIV BRINGS OUT DEADLY CANCERS

2020 ◽  
pp. 1-5
Author(s):  
Camila A Carlman ◽  
Bharat Mishra ◽  
Anita Patel
Keyword(s):  
Immune System ◽  
Hodgkin Lymphoma ◽  
Cancer Progression ◽  
Kaposi's Sarcoma ◽  
Cellular Proliferation ◽  
Kaposi’S Sarcoma ◽  
Hiv Patients ◽  
Non Hodgkin Lymphoma ◽  
Increased Risk ◽  
Risk Of Cancer

Human Immunodeficiency Virus (HIV) infection is both infectious and contagious disease. The people infected with HIV have an increased risk of cancer while comparing with uninfected people. Kaposi’s sarcoma, aggressive B-cell Non-Hodgkin Lymphoma & cervical cancer are the three types of cancers which are termed as “HIV –associated cancers”. Apart from these cancers, HIV patients are prone to cancers of anus, liver, lung, pharynx which are termed as “non-AIDS defining cancers”. Viral oncogenesis and cytokine induced growth contribute to the development of Kaposi sarcoma. Several virally encoded genes such as bcl-2, IL-6, cyclin-D, GPCR & interferon regulatory factor, plays key role in cellular proliferation and survival.  Infection with HIV weakens the immune system and reduces the body’s ability to fight against viral infections that may lead to cancer. Immunosuppression and inflammation in HIV patients also contribute to cancer progression. The complications of AIDS- related cancers include easy bleeding and bruising, tiredness, nausea, vomiting, poor appetite, mouth sores, hair loss etc. According to the data, HIV infected males are more susceptible to Kaposi’s sarcoma and Non- Hodgkin Lymphoma whereas females are more liable to cervical cancers. Early diagnosis and treatment options help to drop the risk of AIDS related cancers. The HAART therapy reduces the risk of cancer in HIV patients by lowering the amount of HIV circulating in blood, so that function of immune system to fight against the virus can be restored. Other treatment methods are chemotherapy, immunotherapy, radiation and surgery.

Risk of non-Hodgkin lymphoma and Kaposi's sarcoma in homosexual men

The Lancet ◽  
1990 ◽  
Vol 336 (8709) ◽  
pp. 248-249 ◽  
Author(s):  
CharlesS Rabkin ◽  
JamesJ Goedert
Keyword(s):  
Hodgkin Lymphoma ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Homosexual Men ◽  
Non Hodgkin Lymphoma

ABV (doxorubicin [Adriamycin], bleomicin and vincristine) polychemotherapy regimen in HIV Kaposi’s Sarcoma: Uruguaian 10-year experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9559-9559 ◽  
Author(s):  
G. Krygier ◽  
A. Sosa ◽  
A. Blanco ◽  
K. Lombardo ◽  
C. Castillo ◽  
...  
Keyword(s):  
Viral Load ◽  
Partial Response ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Severe Toxicity ◽  
Effective Treatment Option ◽  
Hiv Patients ◽  
Non Hodgkin Lymphoma ◽  
Grade 3 ◽  
Aids Clinical Trials

9559 Background: Kaposi’s sarcoma is the most common malignancy among HIV patients and is considered to be one of the AIDS defining conditions. This abstract illustrates our 10 year experience with the treatment of 32 Kaposi’s sarcoma HIV patients with the same therapeutic approach. Methods: Between 04/95 and 03/05 we recruited 32 previously untreated patients that were diagnosed with Kaposi’s sarcoma and treated at the Servicio de Oncologia Clinica (Universitary Clinicas Hospital) in Montevideo. All of them received the same iv polychemotherapy plan (Adriamycin 10mg/m2, Bleomycin 10 U/m2 and Vincristine 1.4 mg/m2, every two weeks until tumor progression or severe toxicity). Results: 21 of the patients were good risk ones and the remaining 11 were poor risk patients (AIDS Clinical Trials Group staging classification). CD4 levels varied from 6 to 780/ml and the viral load ranges were 240 to 89000 copies. The patients received an average of 10.2 (4–21) polychemotherapy cycles. Grade 3–4 myelotoxicity was reported in 5 patients delaying the onset of the subsequent cycles. Grade 2 neurotoxicity was seen in 7 patients after 4, 5, 6, 8, 10, 11 and 13 cycles of ABV, changing vincristine for vinblastine (4mg/m2 every two weeks) in these patients. All the patients achieved a partial response with improvements in CD4 levels and viral load. 13/32 patients experienced a relapse (3–29 months after last chemotherapy cycle). 3 patients were retreated with paclitaxel 135 mg/m2 with 2/3 new partial responses of shorter duration. 5 patients received 4 additional ABV cycles achieving a new partial response. 5 patients refused further treatment dying due to progressive disease. One relapsed patient developed a second malignancy (High grade Non Hodgkin lymphoma) dying three months later. Conclusions: These data suggest that ABV regimen is still an effective treatment option for HIV-Kaposi’s sarcoma, specially in the undeveloped countries in which the cost of other better internationally approved options (liposomal doxorubicin and daunorubicin) makes them unaccesible for the majority of the population. No significant financial relationships to disclose.

scholarly journals A study on otorhinolaryngologic manifestations in human immunodeficiency virus infected patients

2020 ◽  
Vol 6 (3) ◽  
pp. 471
Author(s):  
Shanmuga Ashok S. ◽  
Rajendran S.
Keyword(s):  
Herpes Simplex ◽  
Hiv Infection ◽  
Tamil Nadu ◽  
Kaposi's Sarcoma ◽  
Oral Candidiasis ◽  
Kaposi’S Sarcoma ◽  
Aids Patients ◽  
Oral Hairy Leukoplakia ◽  
Hairy Leukoplakia ◽  
Hiv Aids

<p class="abstract"><strong><span lang="EN-US">Background: </span></strong>The main aim of this study was to find out the ear, nose, and throat (ENT) manifestations in a selected regional population of 100 HIV infected patients, to identify the commoner ENT manifestations among them and to make these manifestations, a guide for regional ENT surgeons, to diagnose HIV/AIDS patients early and to treat them accordingly.</p><p class="abstract"><strong><span lang="EN-US">Methods: </span></strong>The study was a prospective study which was conducted for a period of five years which included 100 HIV seropositive patients, among the patients attending the Outpatient Department of the Otorhinolaryngology and anti-retroviral therapy centre across Government Hospitals in Tamil Nadu according to our inclusion or exclusion criteria. Detailed ENT clinical examination as well as laboratory investigations were carried out to evaluate the nature of ENT presentations of HIV infection.  </p><p class="abstract"><strong><span lang="EN-US">Results: </span></strong>Out of the 100 HIV positive patients, who had some form of ENT symptoms, the most common ENT manifestation in HIV/AIDS was oral candidiasis (40%) followed by cervical lymphadenopathy (30%). Other common manifestations are oral herpes simplex and sensorineural hearing loss. Less common manifestations are chronic sinusitis, tuberculous laryngitis, chronic otitis media, oral hairy leukoplakia, nasal polyps and Kaposi’s sarcoma. Oral candidiasis, chronic/recurrent mucocutaneous herpes simplex, oral hairy leukoplakia and Kaposi’s sarcoma are the AIDS defining illnesses. Oral hairy leukoplakia, is pathognomonic of HIV infection.</p><p class="abstract"><strong><span lang="EN-US">Conclusions: </span></strong>These manifestations help ENT surgeons, to recognize HIV/AIDS patients from the specific ENT lesions occurring in them, for early diagnosis and subsequent treatment.</p>

Classic Kaposi's sarcoma on the glans penis only: Case report

1997 ◽  
Vol 64 (1) ◽  
pp. 134-135
Author(s):  
E. Gastaldi ◽  
S. Benvenuti ◽  
B. Mennini ◽  
M. Iacoviello ◽  
M. Caviglione ◽  
...  
Keyword(s):  
Case Report ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Positive Patient ◽  
Glans Penis ◽  
Hiv Positive ◽  
Partial Penectomy

The Authors report a case of Kaposi's sarcoma presenting on the glans penis only in a non-HIV positive patient, who had not been treated with immuno-suppressive drugs. In our experience and according to a review of specific literature, choice treatment would seem to be a radiotherapeutic approach followed by partial penectomy in the event of recurrence.

scholarly journals HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons

AIDS ◽  
2011 ◽  
Vol 25 (14) ◽  
pp. 1771-1777 ◽  
Author(s):  
Chun Chao ◽  
Lanfang Xu ◽  
Donald I. Abrams ◽  
William J. Towner ◽  
Michael A. Horberg ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Hiv Positive ◽  
Hmg Coa Reductase ◽  
Non Hodgkin Lymphoma ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase
Sign in / Sign up

Export Citation Format

Share Document